Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPD: GOLDEN-4 (Glycopyrrolate for Obstructive Lung Disease Via Electronic Nebulizer
Conditions
Interventions
SUN-101 50 mcg BID eFlow (CS) nebulizer
SUN-101 25 mcg BID eFlow (CS) nebulizer
+1 more
Locations
45
United States
SEC Lung, LLC
Andalusia, Alabama, United States
Jasper Summit Research, LLC
Jasper, Alabama, United States
Pulmonary Associates, PA
Glendale, Arizona, United States
Phoenix Medical Research Institute, LLC
Peoria, Arizona, United States
Clinical Research Consortium
Tempe, Arizona, United States
Center for Clinical Trials of Sacramento, Inc.
Sacramento, California, United States
Start Date
February 1, 2015
Primary Completion Date
December 1, 2015
Completion Date
December 1, 2015
Last Updated
March 13, 2018
NCT05746039
NCT07190209
NCT07307781
NCT07383896
NCT07073950
NCT07518472
Lead Sponsor
Sunovion Respiratory Development Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions